Ligand Pharmaceuticals (LGND) Cash from Financing Activities (2010 - 2026)

Ligand Pharmaceuticals has reported Cash from Financing Activities for 17 years, with the latest figure at -$14.1 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 197.72% year-over-year to -$14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $418.8 million (up 422.16% YoY) and the FY2025 annual result came in at $428.2 million, up 340.83% from the prior year.
• Cash from Financing Activities eased to -$14.1 million in Q1 2026 per LGND's latest filing, from $8.3 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $409.6 million in Q3 2025 and troughed at -$170.4 million in Q1 2022.
• A 5-year average of $10.3 million and a median of $3.3 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities sank 10504.94% in 2022, then soared 1671.87% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$5.3 million in 2022, then jumped by 200.32% to $5.3 million in 2023, then soared by 283.59% to $20.4 million in 2024, then sank by 59.14% to $8.3 million in 2025, then sank by 269.66% to -$14.1 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$14.1 million, $8.3 million, and $409.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.